Hunigton

Teva Pharmaceutical Industries is seeking approval from the US Food and Drug Administration (FDA) for its SD-809 (deutetrabenazine) for treatment in Huntington’s disease (HD).

FDA has accepted the firm’s new drug application (NDA) for SD-809 to treat chorea associated with HD, a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain.

The SD-809 is an investigational, oral and small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2), which is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain.

Teva global R&D president and chief scientific officer Dr Michael Hayden said: "The opportunity to bring a new treatment option to those battling the devastating illness of Huntington’s disease is an important first step and an indication of our profound commitment to improving the lives of patients with this and other debilitating movement disorders."

The NDA was submitted based on positive results from two Phase-III studies, FIRST-HD and ARC-HD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SD-809 reduced chorea in patients with HD in the placebo-controlled and randomised FIRST-HD study.

ARC-HD study’s positive top-line data showed that patients were able to safely convert from tetrabenazine to SD-809 overnight with continued control of chorea.

The FDA granted orphan drug status for SD-809 to treat HD in November 2014, while it was included in the firm’s CNS portfolio with the acquisition of Auspex Pharmaceuticals in May this year.


Image: Coronal section from MR brain scan of a patient with HD. Photo: courtesy of Frank Gaillard.